TORONTO, ONTARIO – CardioComm Solutions, Inc. (TSX VENTURE: EKG) (“CardioComm” or the “Company”), a leading global medical provider of consumer heart monitoring and electrocardiogram (“ECG”) acquisition and management software solutions, announced today that its GEMS™ Universal ECG app (“GEMS™ Universal”), a version of the Company’s US Food and Drug Administration (“FDA”) cleared and Health Canada approved GEMS™ Mobile ECG app, is now available for download from the Google Play store and will be available on Apple’s App Store within the next two weeks.
GEMS™ Universal ECG is compatible with several OEM and private-label handheld ECG devices, including those manufactured by Beijing Choice (P10), BORSAM Biomedical Instruments (WeCardio), BodiMetrics (Check Me and Vitals Rx), Cardiac Design (ECG Check) and Contec Medical Systems (PM10). CardioComm will continue to expand device compatibility on an on-going basis.
GEMS™ Universal is a slimmed-down version of the Company’s Health Canada approved, FDA cleared and CE Mark-certified, hospital-based Global ECG Management System (GEMSTM). GEMS™ Universal will target non-HeartCheck™ branded ECG device users, and will allow for access to CardioComm’s fee-for-use SMART Monitoring ECG reading service, through which users can generate unlimited, medical-grade ECG PDFs or request a review of their ECGs on a fee-for-review basis to confirm the presence or absence of arrhythmias.
GEMS™ Universal will be available under two subscription fee models:
- A monthly Subscription: $6 US monthly with one free ECG interpretation included with each renewal.
- An annual Subscription: $69 US annually with 12 free ECG interpretations included that can be requested at any time during the renewable one year subscription.
Once the free ECG reviews have been used, additional readings may be requested for $1.99 US for an ECG triage or $12.50 US for a physician interpretation.
CardioComm will leverage the existing market presence, brand awareness, and well developed distribution channels of its new device partners to build sales and generate revenues for its GEMS™ Universal ECG app. To ensure engagement, CardioComm will share revenues generated from the subscription fees for the GEMS™ Universal app and from SMART Monitoring ECG readings with device manufacturers. Revenue sharing and percentages will be contingent upon device manufacturers actively promoting the use of GEMS™ Universal with their devices. In some instances, GEMS™ Universal will be promoted as the only English language app for foreign device manufacturers. Marketing and promotion will include GEMS™ Universal ECG and CardioComm branding and promotion through their websites and distribution networks. Device partners will also be required to advertise and run demos of GEMS™ Universal with devices at trade shows in regions where they have already established sales channels and hardware sales.
For further updates regarding GEMSTM Mobile ECG device partnerships please see the Company’s websites at
www.cardiocommsolutions.com and www.theheartcheck.com.